Stance Capital LLC Makes New Investment in The Clorox Company $CLX

Stance Capital LLC acquired a new stake in shares of The Clorox Company (NYSE:CLX) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 12,989 shares of the company’s stock, valued at approximately $1,560,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Nuveen LLC acquired a new stake in Clorox during the first quarter worth about $42,300,000. Public Sector Pension Investment Board increased its position in Clorox by 7.2% during the 1st quarter. Public Sector Pension Investment Board now owns 16,644 shares of the company’s stock worth $2,451,000 after purchasing an additional 1,122 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. increased its position in Clorox by 11.6% during the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 4,242 shares of the company’s stock worth $625,000 after purchasing an additional 442 shares in the last quarter. Kovitz Investment Group Partners LLC raised its holdings in Clorox by 14.5% in the first quarter. Kovitz Investment Group Partners LLC now owns 9,304 shares of the company’s stock valued at $1,370,000 after buying an additional 1,180 shares during the period. Finally, Fox Run Management L.L.C. acquired a new position in Clorox during the first quarter valued at approximately $678,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.

Clorox Stock Performance

Clorox stock opened at $103.98 on Friday. The company has a current ratio of 0.76, a quick ratio of 0.50 and a debt-to-equity ratio of 18.01. The stock has a 50 day moving average of $109.89 and a 200-day moving average of $119.22. The stock has a market cap of $12.68 billion, a P/E ratio of 16.32, a price-to-earnings-growth ratio of 0.52 and a beta of 0.57. The Clorox Company has a 52 week low of $98.20 and a 52 week high of $166.35.

Clorox (NYSE:CLX) last posted its quarterly earnings data on Monday, November 3rd. The company reported $0.85 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.07. The firm had revenue of $1.43 billion for the quarter, compared to the consensus estimate of $1.41 billion. Clorox had a net margin of 11.68% and a return on equity of 358.39%. The firm’s revenue was down 18.9% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.86 EPS. Clorox has set its FY 2026 guidance at 5.950-6.300 EPS. On average, analysts expect that The Clorox Company will post 7.15 EPS for the current fiscal year.

Clorox Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Wednesday, January 28th will be paid a dividend of $1.24 per share. The ex-dividend date is Wednesday, January 28th. This represents a $4.96 annualized dividend and a yield of 4.8%. Clorox’s dividend payout ratio is presently 77.86%.

Insider Buying and Selling

In other news, Director Pierre R. Breber bought 4,000 shares of the firm’s stock in a transaction dated Friday, November 21st. The stock was bought at an average price of $104.13 per share, for a total transaction of $416,520.00. Following the transaction, the director owned 13,000 shares in the company, valued at $1,353,690. The trade was a 44.44% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. 0.63% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on the stock. Jefferies Financial Group reissued a “buy” rating and issued a $152.00 price objective on shares of Clorox in a research report on Tuesday, November 4th. UBS Group set a $119.00 price objective on Clorox and gave the company a “neutral” rating in a research report on Tuesday, November 4th. Morgan Stanley lowered their target price on Clorox from $137.00 to $125.00 and set an “equal weight” rating for the company in a research note on Tuesday, November 4th. Bank of America reduced their price target on Clorox from $135.00 to $125.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 8th. Finally, Wells Fargo & Company lowered their price objective on shares of Clorox from $125.00 to $117.00 and set an “equal weight” rating for the company in a research report on Tuesday, November 4th. One investment analyst has rated the stock with a Buy rating, thirteen have issued a Hold rating and four have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $125.69.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.